Xsolla Elevates Game Monetization and Distribution With Unified Web Shop and Offerwall
13.8.2025 21:00:00 CEST | Business Wire | Press Release
Xsolla, a global commerce company helping developers launch, grow and monetize their games, announces today the expansion of its Offerwall solution with full integration into Xsolla Web Shop, providing game developers with a fully unified and robust monetization stack. This marks the next phase of the Xsolla Offerwall's evolution, which officially launched in March. Additionally, the company announced the launch of the Xsolla Incentive Program, providing game developers with free user acquisition credits to help accelerate game growth by leveraging Xsolla’s commerce infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813734646/en/
(Graphic: Xsolla)
As game developers continue to face challenges monetizing non-paying players, the Xsolla Offerwall offers a new way to unlock value from their entire user base, by allowing players to earn in-game rewards by completing quests, app trials, surveys, and more directly within a developer’s branded Web Shop, without ever leaving the storefront or compromising the player experience.
Unlock Incremental Revenue From Every Player
The integration of Xsolla Offerwall into Web Shop gives developers a unified monetization and distribution platform, with key benefits including:
- New Revenue from Non-Paying Users: Reward users in-game for completing offers.
- Seamless Storefront Experience: Players complete actions and redeem rewards without leaving the game or Web Shop.
- Increased Retention and Conversion: Offerwall users show 7x higher retention by Day 30 and are 10–14x more likely to convert into paying users.
- Flexible Monetization at Scale: With up to 90% revenue share, developers retain more earnings and gain flexibility across global markets.
- Seamless Integration: Xsolla Offerwall can be added to the Web Shop within minutes, with zero coding required.
Sustainable Growth, Backed by the Xsolla Incentive Program
To maximize scale and user engagement, the new Xsolla Incentive Program gives developers who enable both Web Shop and Offerwall:
- Access to Xsolla-funded UA budget to drive traffic and engagement
- Performance-based bonus incentives tied to offerwall usage and storefront purchases
- Full onboarding and marketing support for a fast, effective launch
Proven Impact
Games that integrate offerwalls see a meaningful uplift in both monetization and engagement*:
- 30–40% increase in ad revenue
- 3–5% overall revenue growth
- 7x higher Day 30 retention
- 10–14x higher conversion to in-app purchases
- Up to 120% LTV increase among daily offerwall users
Further enhancing the outcomes that game developers experience through integrating the Web Shop**:
- 40% conversion rate from visit to purchase
- 60% repeat purchase rate
- 15% LTV growth
* Industry stats, July 2025 |
** Xsolla internal metrics, July 2025 |
Xsolla further supports developers by offering a free User Acquisition budget through its Incentive Program, helping teams re-engage non-paying players and convert them into paying users directly through their Web Shop.
“The integration of Offerwall into Web Shop marks an important evolution in how we support developers,” said Chris Hewish, President at Xsolla. “It’s not just about unlocking new revenue, it’s about giving teams a toolkit to convert engagement into value, reach new audiences, and grow sustainably, all from one unified storefront.”
“We were looking for a way to monetize our non-spending users, without disrupting the player experience,” said Founder and CEO, Jorge Lorenzon, at Buldogo Games. “Implementing the Xsolla Offerwall into our existing Web Shop provides us with a new revenue stream, while driving player engagement. The integration was fast and straightforward, and the Xsolla team provided excellent support along the way.”
Xsolla Offerwall is now available globally through Web Shop, enabling developers a new way to monetize non-paying players: www.xsolla.com/offerwall.
Looking to maximize impact? Join the Xsolla Incentive Program to unlock free UA support and grow your Web Shop: www.xsolla.com/incentive-program.
For a complete list of enhancements and developer tools, visit: xsolla.pro/rws25offerwallwebshop.
About Xsolla
Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game.
For more information, visit xsolla.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250813734646/en/
Contacts
Media Contact
Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom